[{"id":"4012ef46-eb93-4087-876c-82a648c0d4c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05400915","created_at":"2022-06-02T16:58:54.112Z","updated_at":"2024-07-02T16:35:29.638Z","phase":"Phase 1/2","brief_title":"Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients","source_id_and_acronym":"NCT05400915","lead_sponsor":"Yonsei University","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 amplification • HER-2 expression • EGFR amplification • EGFR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 amplification • HER-2 expression • EGFR amplification • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • varlitinib (ASLAN001)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 07/23/2019","start_date":" 07/23/2019","primary_txt":" Primary completion: 12/13/2021","primary_completion_date":" 12/13/2021","study_txt":" Completion: 06/13/2022","study_completion_date":" 06/13/2022","last_update_posted":"2023-11-10"},{"id":"e30cc156-1df6-4a00-88be-281a39181009","acronym":"","url":"https://clinicaltrials.gov/study/NCT03130790","created_at":"2021-01-18T15:25:33.383Z","updated_at":"2024-07-02T16:36:17.141Z","phase":"Phase 2/3","brief_title":"Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)","source_id_and_acronym":"NCT03130790","lead_sponsor":"Aslan Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • varlitinib (ASLAN001)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 08/31/2017","start_date":" 08/31/2017","primary_txt":" Primary completion: 12/20/2018","primary_completion_date":" 12/20/2018","study_txt":" Completion: 02/22/2019","study_completion_date":" 02/22/2019","last_update_posted":"2022-02-15"},{"id":"cab84444-6072-42c8-a38d-66350fb897a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02435927","created_at":"2021-01-18T11:39:47.400Z","updated_at":"2024-07-02T16:36:31.065Z","phase":"Phase 1","brief_title":"ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin","source_id_and_acronym":"NCT02435927","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" EGFR • HER-2","pipe":"","alterations":" ","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • varlitinib (ASLAN001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2021-04-28"},{"id":"debbc7f6-6abf-4c23-8351-b1a08b367098","acronym":"","url":"https://clinicaltrials.gov/study/NCT00278902","created_at":"2021-01-18T00:57:01.064Z","updated_at":"2024-07-02T16:36:40.028Z","phase":"Phase 1","brief_title":"A Study of ARRY-334543 in Patients With Advanced Cancer","source_id_and_acronym":"NCT00278902","lead_sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e varlitinib (ASLAN001)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 01/01/2006","start_date":" 01/01/2006","primary_txt":" Primary completion: 06/01/2009","primary_completion_date":" 06/01/2009","study_txt":" Completion: 06/01/2009","study_completion_date":" 06/01/2009","last_update_posted":"2020-10-14"},{"id":"fea3c67c-963c-45dd-8477-ac3d8746f7a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03129074","created_at":"2021-02-22T06:52:42.666Z","updated_at":"2024-07-02T16:37:10.558Z","phase":"Phase 2","brief_title":"Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer","source_id_and_acronym":"NCT03129074","lead_sponsor":"Aslan Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • varlitinib (ASLAN001)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2018","start_date":" 05/01/2018","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2018-05-23"},{"id":"d0a26368-3c02-4fa9-b61e-1255df965ddd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499626","created_at":"2021-01-18T17:13:41.549Z","updated_at":"2024-07-02T16:37:11.507Z","phase":"Phase 1b","brief_title":"Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT03499626","lead_sponsor":"National University Hospital, Singapore","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Lenvima (lenvatinib) • varlitinib (ASLAN001)"],"overall_status":"Unknown status","enrollment":" Enrollment 22","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 05/05/2019","primary_completion_date":" 05/05/2019","study_txt":" Completion: 05/05/2021","study_completion_date":" 05/05/2021","last_update_posted":"2018-04-17"},{"id":"fe5aeca2-231f-44cf-89ca-2513f8ff4ed3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02396108","created_at":"2021-01-18T11:25:52.298Z","updated_at":"2024-07-02T16:37:25.990Z","phase":"Phase 2","brief_title":"Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02396108","lead_sponsor":"National University Hospital, Singapore","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • varlitinib (ASLAN001)"],"overall_status":"Unknown status","enrollment":" Enrollment 55","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2017-02-03"}]